Biocidal Products Regulation

Date: 01/09/15

Biocidal Products Regulation

The Biocidal Products Regulation (BPR) was adopted on 22 May 2012, and became applicable as of 1st September 2013. The objective of the Regulation is to improve the functioning of the European market in biocidal products, whilst ensuring a high level of environmental and human health protection.   

From 1st September 2015 a biocidal active substance will not be legally on the market in the EU unless the substance and supplier are listed on a positive list of active substance suppliers generated by the European Chemicals Agency (ECHA). This is the so-called “Article 95 List”. The objective of Article 95 of the BPR is to ensure that the costs of generating data and supporting active substances are shared fairly.  

As a consequence of Article 95, in order to continue to place any biocidal products onto the EU market after the 1st September 2015 any formulator (such as Kilco) must  purchase any biocidal active substances from a company that is listed on the ECHA Article 95 List. Furthermore, formulators must be able to demonstrate a clear, auditable trail showing that the supply of the active substance used in the product is from a specific Article 95 listed company. Compliance with Article 95 is legally enforcable.   
Kilco (International) Ltd have demonstrated our longstanding commitment to complying with the Biocidal Products Regulation (and the previous Directive) by our participation (as members of the Iodine Registration Group) in the review programme which successfully supported iodine as a biocidal active in line with the requirements of the BPR, and as such Kilco can be found on the Article 95 List as a product and substance supplier.    

We are committed to ongoing compliance with the BPR by sourcing all our biocidal active substances from reputable suppliers included on the Article 95 list, and by generating the required data to support our core product range through the BPR Product Authorisation process.

If you have any questions about the impact of Article 95 of the BPR and the Kilco product range, please do not hesitate to contact us.

Yours Sincerely,    
Dr Martin Garland
MPharm MPSNI MRSC  Technical Director

0 Comment

Nobody has commented yet. Why not add one?

Add your Comment

We have the ability to edit and/or delete posts and comments. Links should be relevant to the topics. Please note all comments are subject to review before inclusion.

Register to comment